AUA

Increasing the frequency setting on a holmium:YAG laser increases stone fragmentation, but determining the saturation point at which efficiency plateaus requires further study.

The majority of medication prescribed to patients undergoing outpatient urologic procedures goes unused, prospective data reveal.

An analysis of Medicare expenditures in the first year after a diagnosis of prostate cancer shows that 5% of patients account for almost 25% of the total spending.

The use of enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA) show differences in overall survival and health care costs when used to treat chemotherapy-naïve metastatic castrate-resistant prostate cancer.

With the AUA annual meeting quickly approaching, Victor W. Nitti, MD, chair of the AUA Office of Education, provides a snapshot of new course offerings and other AUA educational opportunities.

In advance of this year’s AUA annual meeting, Urology Times asked members of our editorial board to choose the top presentations in their subspecialty.

Ray Painter, MD, and Mark Painter also answer coding questions regarding vasectomy and code 50543.

Men with large prostates experience more relief from BPH with treatment by Aquablation therapy (using the AquaBeam System) than with transurethral resection of the prostate, researchers say.

Many urologists don't follow guidelines calling on them to image their patients after ureteroscopic stone disease treatment, researchers say.

Henry Rosevear, MD, explains how he left the AUA annual meeting in San Francisco a smarter urologist.  

In this interview, Jamin Brahmbhatt, MD, gives his take on several studies of orchialgia and chronic prostatitis/chronic pelvic pain syndrome presented at the 2018 AUA annual meeting.

Arthur L. Burnett, II, MD, MBA, discusses some of the significant differences between the 2018 and 2005 AUA guidelines on ED as well as how the new guideline addresses novel treatments that are not currently FDA approved.

In this video, Benjamin M. Brucker, MD, explains the use of clinical care pathways to manage overactive bladder and outlines the benefits of SUFU’s Overactive Bladder Clinical Care Pathway.

Anne E. Calvaresi, DNP, CRNP, RNFA, also discusses best practices that urologists and APPs can follow to ensure they work together well as a team and offers her opinion on the controversy surrounding the use of APPs for performing certain urologic procedures.

In this video, Alan J. Wein, MD, PhD, discusses recent developments in the management of nocturia, including a new FDA-approved agent; underlying causes; and the role of a voiding diary in patient care.

Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.

In this interview, Steven A. Kaplan, MD, highlights the key updates to the 2018 guideline that differentiates it from the AUA’s 2010 guideline on this topic.

Statin use by patients with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy may increase overall survival and prostate cancer-specific survival.

A private urology practice can successfully transform itself from a fee-for-service payment model for cancer care to an episode-based system, although it remains to be determined whether operating under this model also translates into cost savings.

“Patients should be informed of the less-than-ideal stone-free rates and secondary morbidity when residual fragments are present after this treatment modality,” says researcher Igor Sorokin, MD.

The decline occurred despite a consistent number of monthly clinical encounters with a primary diagnosis of hypogonadism.

The analysis “gives urologists the first accurate idea of how many physician assistants and nurse practitioners are working in urology,” says researcher Raymond Fang.

New study findings provide evidence to guide management decisions for patients with prostate cancer who have lymph node metastases following radical prostatectomy.

The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.

Listen to the interview of Dr. Neil Baum share his top five places to eat and attractions you won't want to miss out on while attending the 2015 AUA annual meeting.

Sophisticated, fun, historic, and some say magical. New Orleans is all that and much more, including home to some of the nation’s best dining venues and most famous chefs.

The AUA returns to Orlando-one of the nation’s most family-friendly, fun cities-for its 2014 annual meeting, May 16-21. Although this central Florida town is most frequently associated with a certain beloved mouse-and Disney’s many parks are well worth a visit, regardless of your age-there are plenty of other activities to make all ages smile.

Resources to help you understand the current state of the urology work force, including trends specific to your county, and future projections. Watch for updates to this page as they become available!

Attendees of the 2013 AUA annual meeting offer their take on the urologist shortage and what should be done about it.

San Diego is hosting the AUA annual meeting this year, May 4-8. This Southern California city offers a great climate in which to enjoy the outdoors while also attending the year’s preeminent urology meeting.